The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 13, 2018
Filed:
Apr. 08, 2016
Applicant:
Texas Biomedical Research Institute, San Antonio, TX (US);
Inventors:
Ruth M. Ruprecht, Boston, MA (US);
Michael Humbert, Boston, MA (US);
Assignee:
Texas Biomedical Research Institute, San Antonio, TX (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/00 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); A61K 39/21 (2006.01); C07K 16/10 (2006.01); C07K 16/42 (2006.01); C12N 7/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 39/12 (2013.01); A61K 39/21 (2013.01); C07K 16/1063 (2013.01); C07K 16/4216 (2013.01); C12N 7/00 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/575 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C07K 2318/10 (2013.01); C07K 2319/00 (2013.01); C12N 2740/15022 (2013.01); C12N 2740/16122 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16171 (2013.01); C12N 2795/00043 (2013.01);
Abstract
The invention provides methods, compositions and kits for treating and or preventing an HIV infection. For example, HIV envelope-like polypeptides (wild-type HIV polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to HIV. Alternatively, antibodies directed to the HIV envelope-like polypeptides may be administered to an individual to treat or prevent an HIV infection and/or one or more symptoms associated with the infection (e.g., AIDS).